^
Association details:
| Biomarker: | HER-2 amplification + RAS wild-type + BRAF wild-type |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/25/2023
Excerpt:
Rectal cancer….Primary Treatment….Previous adjuvant FOLFOX/CAPEOX within past 12 mo…fam trastuzumab deruxtecan-nxki (HER2-amplified and RAS and BRAF WT)
